BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings’ Surgical and Wound Care Business

Core Viewpoint - BioStem Technologies, Inc. has acquired the surgical and wound care business of BioTissue Holdings Inc. for approximately $15 million, enhancing its commercial organization and expanding its market reach in advanced wound care [1][4][5]. Group 1: Acquisition Details - BioStem has closed a definitive asset purchase agreement with BioTissue, acquiring its full portfolio of surgical and wound care assets, including the Neox and Clarix product lines [2][3]. - The acquisition includes a nationwide network of sales representatives and independent agents, along with key GPO contracts, significantly expanding BioStem's commercial capabilities [2][3]. - The total upfront cash payment for the acquisition is approximately $15 million, with potential additional payments of up to $25 million based on regulatory and commercial milestones [4][5]. Group 2: Financial Impact - The acquired assets generated approximately $29 million in sales in 2025 and are expected to contribute positively to BioStem's EBITDA in 2026 [5]. - Post-acquisition, BioStem's cash and restricted cash balance is approximately $16 million [5]. Group 3: Leadership Changes - Barry Hassett has been promoted to Chief Commercial Officer to lead the newly combined commercial team, bringing over 25 years of industry experience [6].